{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T06:42:16Z","timestamp":1740120136134,"version":"3.37.3"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T00:00:00Z","timestamp":1711324800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T00:00:00Z","timestamp":1711324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s12185-024-03762-8","type":"journal-article","created":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T05:10:45Z","timestamp":1711343445000},"page":"762-767","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sustained remission after cord blood transplantation for breast cancer with lung metastases and myelodysplastic syndrome"],"prefix":"10.1007","volume":"119","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4336-1952","authenticated-orcid":false,"given":"Naokazu","family":"Nakamura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nao","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadakazu","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayumi","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Ikunari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomomi","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroko","family":"Tsunemine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"June","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junya","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhito","family":"Nannya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seishi","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akifumi","family":"Takaori-Kondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyoshi","family":"Arima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,25]]},"reference":[{"key":"3762_CR1","doi-asserted-by":"publisher","first-page":"709","DOI":"10.3324\/haematol.2014.113860","volume":"100","author":"CR Cruz","year":"2015","unstructured":"Cruz CR, Bollard CM. T-cell and natural killer cell therapies for hematologic malignancies after hematopoietic stem cell transplantation: enhancing the graft-versus-leukemia effect. Haematologica. 2015;100:709\u201319.","journal-title":"Haematologica"},{"key":"3762_CR2","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.blre.2018.04.002","volume":"32","author":"I Dierckx de Casterl\u00e9","year":"2018","unstructured":"Dierckx de Casterl\u00e9 I, Billiau AD, Sprangers B. Recipient and donor cells in the graft-versus-solid tumor effect: It takes two to tango. Blood Rev. 2018;32:449\u201356.","journal-title":"Blood Rev"},{"issue":"1134","key":"3762_CR3","first-page":"1140","volume":"17","author":"L Barkholt","year":"2006","unstructured":"Barkholt L, Bregni M, Remberger M, Blaise D, Peccatori J, French ITAC group and the EBMT Solid Tumour Working Party, et al. Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe. Ann Oncol. 2006;17(1134):1140.","journal-title":"Ann Oncol"},{"key":"3762_CR4","doi-asserted-by":"publisher","first-page":"3886","DOI":"10.1200\/JCO.2004.01.127","volume":"22","author":"MR Bishop","year":"2004","unstructured":"Bishop MR, Fowler DH, Marchigiani D, Castro K, Kasten-Sportes C, et al. Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer. J Clin Oncol. 2004;22:3886\u201392.","journal-title":"J Clin Oncol"},{"key":"3762_CR5","doi-asserted-by":"publisher","first-page":"e65","DOI":"10.1097\/00006676-200404000-00027","volume":"28","author":"T Takahashi","year":"2004","unstructured":"Takahashi T, Omuro Y, Matsumoto G, Sakamaki H, Maeda Y, et al. Nonmyeloablative allogeneic stem cell transplantation for patients with unresectable pancreatic cancer. Pancreas. 2004;28:e65\u20139.","journal-title":"Pancreas"},{"issue":"418","key":"3762_CR6","first-page":"420","volume":"92","author":"S Secondino","year":"2007","unstructured":"Secondino S, Carrabba MG, Pedrazzoli P, Castagna L, Spina F, European Group for Blood and Marrow Transplantation Solid Tumors Working Party, et al. Reduced intensity stem cell transplantation for advanced soft tissue sarcomas in adults: a retrospective analysis of the European group for blood and marrow transplantation. Haematologica. 2007;92(418):420.","journal-title":"Haematologica"},{"key":"3762_CR7","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/ijc.10555","volume":"101","author":"T Kurokawa","year":"2002","unstructured":"Kurokawa T, Fischer K, Bertz H, Hoegerle S, Finke J, Mackensen A. In vitro and in vivo characterization of graft-versus-tumor responses in melanoma patients after allogeneic peripheral blood stem cell transplantation. Int J Cancer. 2002;101:52\u201360.","journal-title":"Int J Cancer"},{"key":"3762_CR8","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/S0140-6736(05)66989-9","volume":"366","author":"AM Carella","year":"2005","unstructured":"Carella AM, Beltrami G, Corsetti MT, Nati S, Musto P, et al. Reduced intensity conditioning for allograft after cytoreductive autograft in metastatic breast cancer. Lancet. 2005;366:318\u201320.","journal-title":"Lancet"},{"issue":"1703","key":"3762_CR9","first-page":"1719","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia. 2022;36(1703):1719.","journal-title":"Leukemia"},{"key":"3762_CR10","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424\u201347.","journal-title":"Blood"},{"key":"3762_CR11","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","volume":"120","author":"PL Greenberg","year":"2012","unstructured":"Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454\u201365.","journal-title":"Blood"},{"key":"3762_CR12","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1182\/blood.2022018896","volume":"141","author":"T Kewan","year":"2023","unstructured":"Kewan T, Bahaj W, Durmaz A, Aly M, Ogbue OD, et al. Validation of the molecular international prognostic scoring system in patients with myelodysplastic syndromes. Blood. 2023;141:1768\u201372.","journal-title":"Blood"},{"key":"3762_CR13","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912\u20139.","journal-title":"Blood"},{"issue":"7","key":"3762_CR14","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200008","volume":"1","author":"E Bernard","year":"2022","unstructured":"Bernard E, Tuechler H, Greenberg PL, Hasserjian RP, Arango Ossa JE, et al. Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. NEJM Evid. 2022;1(7):EVIDoa2200008.","journal-title":"NEJM Evid."},{"key":"3762_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100114","volume":"6","author":"T Grinda","year":"2021","unstructured":"Grinda T, Antoine A, Jacot W, Blaye C, Cottu PH, et al. Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008\u20132017 ESME cohort. ESMO Open. 2021;6: 100114.","journal-title":"ESMO Open"},{"key":"3762_CR16","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/1471-2407-8-153","volume":"8","author":"GM Callagy","year":"2008","unstructured":"Callagy GM, Webber MJ, Pharoah PD, Caldas C. Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer. BMC Cancer. 2008;8:153.","journal-title":"BMC Cancer"},{"key":"3762_CR17","doi-asserted-by":"publisher","first-page":"3256","DOI":"10.1158\/1078-0432.CCR-21-3811","volume":"28","author":"GJ Lindeman","year":"2022","unstructured":"Lindeman GJ, Fernando TM, Bowen R, Jerzak KJ, Song X, et al. VERONICA: randomized phase II study of fulvestrant and venetoclax in ER-positive metastatic breast cancer post-CDK4\/6 inhibitors\u2014efficacy, safety, and biomarker results. Clin Cancer Res. 2022;28:3256\u201367.","journal-title":"Clin Cancer Res"},{"key":"3762_CR18","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.ccr.2012.08.024","volume":"22","author":"D Sturm","year":"2012","unstructured":"Sturm D, Witt H, Hovestadt V, Khuong-Quang DA, Jones DT, et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell. 2012;22:425\u201337.","journal-title":"Cancer Cell"},{"key":"3762_CR19","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617\u201329.","journal-title":"N Engl J Med"},{"key":"3762_CR20","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3109\/10428190009087014","volume":"38","author":"DH Fowler","year":"2000","unstructured":"Fowler DH, Gress RE. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma. Leuk Lymphoma. 2000;38:221\u201334.","journal-title":"Leuk Lymphoma"},{"key":"3762_CR21","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1093\/stmcls\/sxac021","volume":"40","author":"S Barisic","year":"2022","unstructured":"Barisic S, Childs RW. Graft-versus-solid-tumor effect: from hematopoietic stem cell transplantation to adoptive cell therapies. Stem Cells. 2022;40:556\u201363.","journal-title":"Stem Cells"},{"key":"3762_CR22","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1056\/NEJM199602013340501","volume":"334","author":"E Goulmy","year":"1996","unstructured":"Goulmy E, Schipper R, Pool J, Blokland E, Falkenburg JH, et al. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med. 1996;334:281\u20135.","journal-title":"N Engl J Med"},{"issue":"79","key":"3762_CR23","first-page":"82","volume":"51","author":"N Santos","year":"2016","unstructured":"Santos N, Rodr\u00edguez-Romanos R, Nieto JB, Bu\u00f1o I, Vallejo C, et al. GvHD\/immunotherapy working party of the spanish group of hematopoietic transplant (GETH). UGT2B17 minor histocompatibility mismatch and clinical outcome after HLA-identical sibling donor stem cell transplantation. Bone Marrow Transplant. 2016;51(79):82.","journal-title":"Bone Marrow Transplant"},{"key":"3762_CR24","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","volume":"17","author":"M Cristofanilli","year":"2016","unstructured":"Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17:425\u201339.","journal-title":"Lancet Oncol"},{"key":"3762_CR25","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","volume":"6","author":"GW Sledge Jr","year":"2020","unstructured":"Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, et al. The Effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy\u2014MONARCH 2: a randomized clinical trial. JAMA Oncol. 2020;6:116\u201324.","journal-title":"JAMA Oncol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-024-03762-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-024-03762-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-024-03762-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T16:02:45Z","timestamp":1716998565000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-024-03762-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,25]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["3762"],"URL":"https:\/\/doi.org\/10.1007\/s12185-024-03762-8","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"type":"print","value":"0925-5710"},{"type":"electronic","value":"1865-3774"}],"subject":[],"published":{"date-parts":[[2024,3,25]]},"assertion":[{"value":"6 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing financial interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}